Overview

Rainbow Extension Study

Status:
Active, not recruiting

Trial end date:
2022-05-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the long term efficacy and safety of intravitreal ranibizumab compared with laser ablation therapy in patients who were treated for retinopathy of prematurity (ROP) in the core study CRFB002H2301

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Ranibizumab